CMS/FDA Parallel Review: Agencies Weighing Process For Planning Trials That Satisfy Both
Executive SummaryCMS and FDA are considering a voluntary process that would help drug, biologic and medical device sponsors design clinical trials that would ultimately support both FDA approval and CMS national coverage decisions for Medicare reimbursement.
You may also be interested in...
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.